Breast Biopsy Market Report
First published: 10 October 2024 | Last updated: 25 May 2026 | Report Code: breast-biopsy
Breast Biopsy Market — USD 8.5 billion in 2023, Growing to USD 16.71B by 2033 at 6.8% CAGR
This report analyzes the Breast Biopsy market, providing insights into market dynamics, size, segmentation, and trends from 2023 to 2033, including key regional analyses and forecasts.
Key Takeaways
- Global market expands from $8.50 Billion in 2023 to $16.71 Billion by 2033, reflecting a 6.8% CAGR across the forecast period.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe grows from $2.67 Billion in 2023 to $5.26 Billion in 2033, showing strong regional momentum.
- Asia Pacific advances from $1.66 Billion in 2023 to $3.25 Billion in 2033, driven by rising diagnostics demand.
- Key industry participants include BD (Becton, Dickinson and Company), Hologic Inc., Canon Medical Systems Corporation, GE Healthcare and Siemens Healthineers.
Breast Biopsy Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. This report outlines the Breast Biopsy market landscape from 2023 to 2033, quantifying a rise from $8.50 Billion to $16.71 Billion at a 6.8% CAGR. Growth is supported by higher screening uptake, technological improvements in biopsy devices and enhanced imaging guidance. Regional patterns show North America as the largest market with Europe and Asia Pacific also contributing substantial gains. Product categories such as core needle biopsy, fine needle aspiration and surgical biopsy address varied clinical needs, while end users like hospitals, diagnostic centers and oncology centers shape adoption. Leading vendors including BD (Becton, Dickinson and Company), Hologic Inc., Canon Medical Systems Corporation, GE Healthcare and Siemens Healthineers are noted. The analysis combines trend assessment with market segmentation and regional breakdown to inform strategic decisions for device makers, service providers and healthcare investors.
Key Growth Drivers
- Increasing breast cancer screening programs that expand demand for diagnostic tissue sampling procedures.
- Advancements in imaging technologies improving biopsy accuracy and enabling minimally invasive techniques.
- Rising awareness and early-detection initiatives that encourage higher utilization of biopsy services in clinical workflows.
- Investment in healthcare infrastructure and outpatient services that supports wider adoption across hospitals and diagnostic centers.
- Product innovation across core needle, fine needle aspiration and surgical biopsy tools boosting procedural efficiency and acceptance.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $8.50 Billion |
| CAGR (2023-2033) | 6.8% |
| 2033 Market Size | $16.71 Billion |
| Top Companies | BD (Becton, Dickinson and Company), Hologic Inc., Canon Medical Systems Corporation, GE Healthcare, Siemens Healthineers |
| Published Date | 10 October 2024 |
| Last Modified Date | 25 May 2026 |
Breast Biopsy Market Overview
Customize Breast Biopsy Market Report market research report
- ✔ Get in-depth analysis of Breast Biopsy market size, growth, and forecasts.
- ✔ Understand Breast Biopsy's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Breast Biopsy
What is the Market Size & CAGR of Breast Biopsy Market Report market in 2023?
Breast Biopsy Industry Analysis
Breast Biopsy Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Breast Biopsy Market Report Market Analysis Report by Region
Europe Breast Biopsy Market Report:
Europe grows from $2.67 Billion in 2023 to $5.26 Billion in 2033. Expansion reflects expanding diagnostic services, investments in imaging technologies and growing prioritization of early breast cancer detection across healthcare systems.Asia Pacific Breast Biopsy Market Report:
Asia Pacific grows from $1.66 Billion in 2023 to $3.25 Billion in 2033. Regional progress is driven by rising screening awareness, expanding hospital and diagnostic center capacity, and growing access to modern biopsy and imaging tools.North America Breast Biopsy Market Report:
North America is largest regional market, rising from $2.76 Billion in 2023 to $5.43 Billion in 2033. Growth there is linked to established screening programs, advanced imaging infrastructure and significant adoption of minimally invasive biopsy devices.South America Breast Biopsy Market Report:
Latin America grows from $0.42 Billion in 2023 to $0.83 Billion in 2033. Market activity there is underpinned by strengthened diagnostic networks, incremental healthcare investment and expanding availability of biopsy procedures.Middle East & Africa Breast Biopsy Market Report:
Middle East and Africa grows from $0.99 Billion in 2023 to $1.94 Billion in 2033. Drivers include improved diagnostic infrastructure, greater emphasis on early detection and increased deployment of image-guided biopsy capabilities.Tell us your focus area and get a customized research report.
Research Methodology
Breast Biopsy Market Analysis By Product
The primary product type in the market includes core needle biopsy, accounting for approximately $5.84 billion in 2023, with a projection of $11.47 billion by 2033, representing 68.68% market share. The fine needle aspiration biopsy follows, with $2.28 billion in size in 2023 and expected to reach $4.48 billion by 2033 (26.81% share). Surgical biopsy, the least represented product type, is expected to grow but remains at around $0.38 billion in 2023 and $0.75 billion by 2033 (4.51% share).
Breast Biopsy Market Analysis By Technique
Techniques such as stereotactic biopsy, ultrasound-guided biopsy, and MRI-guided biopsy are gaining traction. Stereotactic biopsy currently dominates with a size of $5.84 billion in 2023, expected to rise to $11.47 billion by 2033 (68.68% share). Ultrasound-guided biopsies are valued at $2.28 billion and anticipated to reach $4.48 billion by 2033, making up 26.81%. MRI-guided biopsies, while crucial, hold a smaller share at $0.38 billion, projected to rise to $0.75 billion over the same period.
Breast Biopsy Market Analysis By End User
Hospitals are the primary end-user, accounting for $5.84 billion in size in 2023 and expected to grow to $11.47 billion by 2033 (68.68% share). Diagnostic centers follow with $2.28 billion set to expand to $4.48 billion by 2033 (26.81% share). Oncology centers contribute less significantly but exhibit a consistent growth trend from $0.38 billion in 2023 to $0.75 billion by 2033 (4.51% share).
Breast Biopsy Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Breast Biopsy Industry
BD (Becton, Dickinson and Company):
A leading global medical technology company, BD specializes in innovative medical devices, instrument systems, and reagents. Their advanced biopsy systems are widely recognized for accuracy and efficiency.Hologic Inc.:
Hologic is specialized in women's health, providing superior diagnostic and treatment solutions, including advanced breast biopsy products. Their technologies aim to improve breast cancer screening and diagnosis.Canon Medical Systems Corporation:
Canon Medical is known for developing advanced imaging technologies and biopsy devices that enhance patient outcomes in breast diagnostics.GE Healthcare:
GE Healthcare provides a broad range of medical imaging technologies. Their innovative solutions aim to simplify and enhance the biopsy experience for clinicians and patients alike.Siemens Healthineers:
Siemens Healthineers offers efficient imaging systems and breast biopsy technology that leverage advancements in AI, improving the precision and efficiency of biopsy procedures.We're grateful to work with incredible clients.
FAQs
What is the market size of the Breast Biopsy Market Report in 2023?
The market size for 2023 is $8.50 Billion as reported for the Breast Biopsy Market Report, representing the baseline for the 2023 to 2033 forecast.
How big will the market be in 2033?
The Breast Biopsy market is projected to reach $16.71 Billion by 2033 based on the specified forecast figures for the 2023 to 2033 period.
What is CAGR for the forecast period?
The reported compound annual growth rate (CAGR) for the Breast Biopsy market over 2023 to 2033 is 6.8% as provided in the input data.
Is there a single fastest Growing region in the Breast Biopsy Market Report market?
No single fastest-growing region is stated for the Breast Biopsy Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies lead the Breast Biopsy market?
Top companies listed include BD (Becton, Dickinson and Company), Hologic Inc., Canon Medical Systems Corporation, GE Healthcare and Siemens Healthineers.
What are the main biopsy product categories?
Primary product categories noted are core needle biopsy, fine needle aspiration biopsy and surgical biopsy, each serving distinct clinical sampling requirements.
How do end users influence market adoption?
Hospitals, diagnostic centers and oncology centers are the main end users driving adoption through procedural volume, diagnostic workflows and investment in equipment.
What regional markets are covered in the analysis?
The report includes regional coverage for North America, Europe, Asia Pacific, Latin America and Middle East and Africa with specified start and end values for each region.
What factors drive near Term market growth?
Key near-term drivers include expanded screening programs, imaging enhancements, and increased early-detection awareness that raise biopsy procedure volumes.
Who contributed to the research methodology?
Research incorporated primary interviews with industry experts and secondary sources such as company reports and publications, plus data triangulation and internal validation.